Study of Pembrolizumab Following TACE in Primary Liver Carcinoma

NCT03397654 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Primary Liver Carcinoma

Interventions

DRUG: Pembrolizumab
COMBINATION_PRODUCT: Trans-arterial chemoembolization

Sponsor

Imperial College London

Collaborators

[object Object]